These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 21197567)
1. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567 [TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer]. Gerson Cwilich R; Alban de la Torre LF; Villalobos Prieto A; Serrano Olvera JA Gac Med Mex; 2012; 148(2):117-24. PubMed ID: 22622310 [TBL] [Abstract][Full Text] [Related]
3. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056 [TBL] [Abstract][Full Text] [Related]
4. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience. Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
6. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. DeMichele A; Putt M; Zhang Y; Glick JH; Norman S Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466 [TBL] [Abstract][Full Text] [Related]
7. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526 [TBL] [Abstract][Full Text] [Related]
8. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Kaplan HG; Malmgren JA; Atwood M Breast J; 2009; 15(5):454-60. PubMed ID: 19671105 [TBL] [Abstract][Full Text] [Related]
9. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
10. Impact of oncotype DX recurrence score in the management of breast cancer cases. Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121 [TBL] [Abstract][Full Text] [Related]
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
12. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
14. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717 [TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877 [TBL] [Abstract][Full Text] [Related]
18. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229 [TBL] [Abstract][Full Text] [Related]
19. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer. Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456 [TBL] [Abstract][Full Text] [Related]
20. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31. Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A Oncology; 2021; 99(11):699-702. PubMed ID: 34425579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]